The Pharma Data

AUGUST 22, 2021

We are very encouraged by these efficacy and safety data in high-risk people, showing our long-acting antibody combination has the potential to protect from symptomatic and severe disease, alongside vaccines. We look forward to sharing further data from the AZD7442 Phase III clinical trial programme later this year.” About AstraZeneca.

Trials 52

Trials Vaccine Virus Pharmacokinetics 52

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. These include inflammation, cancer, infectious disease, and addiction. 1 , 33–43 (2018). & Ohi, R.) 403–421 (Springer, 2016).

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

New Drug Approvals

SEPTEMBER 13, 2024

14] Pharmacokinetics The oral bioavailability of aticaprant is 25%. [1] 14] Pharmacokinetics The oral bioavailability of aticaprant is 25%. [1] 30 January 2018. Reed B, Butelman ER, Fry RS, Kimani R, Kreek MJ (March 2018). 2] Aticaprant is taken by mouth. [1] 1] Side effects of aticaprant include itching , among others.

Treatment 62

Treatment Clinical Trials Pharmacokinetics Pharmaceuticals 62

The Pharma Data

MARCH 13, 2021

HAE is unpredictable, debilitating and potentially life-threatening, and recognition of the disease remains low in Japan, meaning there are significant challenges relating to diagnosis and access to effective therapies,” said Naoyoshi Hirota, General Manager, Takeda Development Center, Japan. Takeda in Hereditary Angioedema. Interactions.

Treatment 52

Treatment Pharmacokinetics Drugs Production 52

The Pharma Data

AUGUST 19, 2021

1 Disease response was evaluated using overall response rate (ORR), per Response Evaluation Criteria in Solid Tumors Version 1.1* (RECIST v1.1) In 2018, Janssen Biotech, Inc. entered into a license and collaboration agreement with Yuhan Corporation for the development of lazertinib. **In 2018, Janssen Biotech, Inc.

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52

The Pharma Data

NOVEMBER 8, 2020

The submission includes data from the ENLIGHTEN clinical development program in schizophrenia, and pharmacokinetic (PK) bridging data comparing ALKS 3831 and Zyprexa (olanzapine), to support an indication for schizophrenia. Celgene acquired it in 2018 from bluebird bio, who originally developed the therapy.

FDA 52

FDA Trials Therapies Pharmacokinetics 52

Metabolite Tales Blog

JANUARY 23, 2024

The drug is therefore contraindicated in cases where severe renal impairment or end‐stage renal disease has been confirmed, as well as in combination with CYP1A2 inhibitors [7]. Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite—Resolution for Clinical Development. link] [11] Zheng et al.,

Small Molecule 52

Small Molecule FDA Approval FDA Pharmacokinetics 52

The Pharma Data

SEPTEMBER 19, 2020

While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Secondary endpoints include OS, event-free survival, disease-free survival and quality of life measures. pCR was observed in 57.6% (95% CI: 49.7–65.2) 2] Yao H et al.

Treatment 52

Treatment Disease Therapies Pharmaceuticals 52

Metabolite Tales Blog

DECEMBER 13, 2023

Pharma Res Per 1 (1), 2013, e00002; [link] [4] Discovery of an oral, rule-of-5 compliant, IL-17A protein-protein interaction modulator (PPIm) for the treatment of psoriasis and other inflammatory diseases. 8(2):3640-3648; [link] [11] Pharmacokinetics of the Multi-kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality.

Small Molecule 59

Small Molecule Metabolic Stability Treatment Pharmacokinetics 59

The Pharma Data

JULY 22, 2021

The prospective, phase 3, open-label, international multicenter study included 23 patients with severe von Willebrand disease (VWD). 1 The pharmacokinetics (PK) of VWF:ristocetin cofactor (VWF:RCo) and FVIII pharmacodynamics (PD) [PB0917] were also studied and presented at the congress. About von Willebrand Disease (VWD).

Treatment 52

Treatment Laboratories Production Disease 52

The Pharma Data

FEBRUARY 8, 2021

ACIS is a Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical study evaluating the efficacy and safety of ERLEADA ® and ZYTIGA ® plus prednisone compared to placebo and ZYTIGA ® plus prednisone in 982 patients with chemotherapy-naïve mCRPC disease who received ADT. FDA on February 8, 2018. [vi]

Pharmaceutical Companies 52

Pharmaceutical Companies Treatment Clinical Trials Therapies 52

The Pharma Data

APRIL 8, 2021

OCREVUS data show its consistent benefit on slowing disease progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS). Data for ENSPRYNG in neuromyelitis optica spectrum disorder (NMOSD) reinforce safety and efficacy, including in patients with concomitant autoimmune diseases (CAIDs). Following U.S.

Clinical Trials 52

Clinical Trials Trials Disease Therapies 52

The Pharma Data

JULY 6, 2021

“Breaking barriers for people living with rare blood disorders requires that we push ourselves to transform the therapeutic landscape, ” said Karin Knobe, MD, PhD, Head of Development, Rare Disease s and Rare Blood Disorders at Sanofi. “We Three additional Phase 2 studies in immunological diseases are planned to start in 2021.

Therapies 52

Therapies Pharmacokinetics RNA Treatment 52

Agency IQ

SEPTEMBER 15, 2023

The committee also made recommendations regarding pharmacokinetic and safety assessments. When looking at several pharmacokinetic studies, the FDA found that the 10 mg oral dose of phenylephrine has a very low bioavailability of less than 1% and, subsequently, low systemic alpha-1 adrenergic activity.

Science 40

Science FDA Clinical Trials Clinical Pharmacology 40

The Pharma Data

FEBRUARY 25, 2021

FIREFISH Part 1 data show treatment with Evrysdi at 12 months helped 90% of these infants survive without permanent ventilation and 33% sit without support, a key motor milestone not normally seen in the natural course of the disease. Enrollment for Part 2 was completed in November 2018. mg/kg for Part 2.

Pharmacokinetics 52

Pharmacokinetics FDA Approval Treatment Disease 52

The Pharma Data

OCTOBER 6, 2021

About AZD7442 AZD7442 is a combination of two LAABs-tixagevimab (AZD8895) and cilgavimab (AZD1061)- decided from B- cells bestowed by convalescent cases after SARS-CoV-2 disease. 2018; 37 (9) 886-892. Chats regarding budget agreements for AZD7442 are ongoing with the US Government as well as other governments around the world.

Pharmacokinetics 52

Pharmacokinetics Trials Government Vaccine 52

The Pharma Data

MARCH 16, 2021

SUNFISH Part 2 study population includes broad range of ages and disease severities, representing a real-world spectrum of people living with Type 2 or 3 SMA. Based on the natural history of the disease, people with Types 2 and 3 SMA who remain untreated decline in motor function over time. The study met its primary endpoint.

Pharmacokinetics 52

Pharmacokinetics Treatment Clinical Trials Disease 52

The Pharma Data

MARCH 30, 2021

SMA is a leading genetic cause of death in infants and 5q SMA is the most common form of the disease. Evrysdi was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation in 2019. Enrolment for Part 2 was completed in November 2018. The study met its primary endpoint.

Treatment 52

Treatment Clinical Trials Pharmacokinetics Trials 52

Agency IQ

FEBRUARY 23, 2024

Obesity itself contributes to multiple long-term consequences , including high blood pressure and high cholesterol, which in turn increase the risk of heart disease. That passage is referred to as pharmacokinetics (PK) and incorporates four important phases – absorption, distribution, metabolism, and excretion (ADME).

Drugs 40

Drugs Clinical Trials Pharmacokinetics Drug Development 40

The Pharma Data

SEPTEMBER 27, 2020

Of the 17 infants treated with the therapeutic dose, two experienced fatal complications of their disease at 8 and 13 months of treatment and one infant was withdrawn from the study and sadly died 3.5 Enrolment for Part 2 was completed in November 2018. About SMA SMA is a severe, progressive neuromuscular disease that can be fatal.

Pharmacokinetics 52

Pharmacokinetics FDA Approval Treatment Clinical Trials 52

Metabolite Tales Blog

NOVEMBER 13, 2024

Major biotransformation routes of aficamten involving hydroxylation, onwards glucuronidation and gut metabolism Hypertrophic cardiomyopathy is a surprisingly common genetic heart disease, affecting 1:200 to 1:500 people in the US. Drug Metab Pharmacokinet. Xu D, Divanji P, Griffith A, et al. Pharmacol Res Perspect. 2024; 12:e70006.

Pharmacokinetics 59

Pharmacokinetics Small Molecule Production Clinical Development 59